Does Omega-3 (EPA/DHA) Deliver? A Clinical Evidence Review for Supplement Professionals

Norway — 13 May 2026

For decades, omega-3 fatty acids, specifically EPA and DHA, have been hailed as nutritional titans, essential for everything from cardiovascular health to cognitive function. But is the industry's unwavering focus on ever-higher concentrations and fish oil sourcing truly sustainable or even clinically warranted? Despite a market value exceeding £6 billion, questions persist regarding the efficacy of many commercial formulations and the environmental cost of their production. Are we overlooking more sustainable, bioavailable, and perhaps equally effective alternatives?

What the Clinical Evidence Actually Shows

The clinical landscape for omega-3s is nuanced, often contradictory, and far from the unequivocal endorsement many marketing campaigns suggest. While observational studies frequently link higher omega-3 intake to reduced cardiovascular events, interventional trials present a more complex picture. For instance, the REDUCE-IT trial demonstrated a significant reduction in major adverse cardiovascular events with 4g/day of icosapent ethyl (an EPA-only ethyl ester), yet this was in a specific high-risk population already on statin therapy. Conversely, the VITAL study, using 1g/day of combined EPA and DHA, showed no significant reduction in cardiovascular events or cancer incidence in a general population. "The effect size often cited in marketing materials rarely reflects the average consumer experience," notes Dr. Eleanor Vance, a nutritional epidemiologist. "Many trials use pharmacological doses or specific populations, which simply do not translate to over-the-counter supplements." Conflicts of interest, particularly from manufacturers funding research, also warrant scrutiny, making independent meta-analyses critical for objective assessment.

The Formulation Reality

Formulators face significant hurdles in delivering effective omega-3 products. Bioavailability remains a key concern, with triglyceride forms generally demonstrating superior absorption compared to ethyl esters, though ethyl esters can achieve higher purity. The stability of these highly unsaturated fatty acids is another major challenge; oxidation leads to rancidity, off-flavours, and potentially reduced efficacy. Antioxidants like tocopherols or rosemary extract are crucial, as are appropriate encapsulation technologies. "The 'concentration wars' often overlook the fundamental issue of oxidative stability," states Professor Alistair Finch, a food chemist. "A 90% concentrate that oxidises quickly on the shelf delivers less active EPA/DHA than a well-stabilised 60% product." Excipient interactions, particularly with minerals, can also accelerate degradation, demanding careful formulation design. Maintaining a low peroxide value (PV) and anisidine value (AV) is paramount for product quality and shelf life.

Market Position and Commercial Viability

The omega-3 market is mature yet continues to see innovation, particularly in sustainable sourcing and high-concentration formats. Projected to grow at a CAGR of 7.5% through 2030, demand remains robust, driven by health awareness. However, this growth is accompanied by intense pricing pressures, especially for standard fish oil concentrates. Manufacturers must contend with significant minimum order quantity (MOQ) requirements from primary ingredient suppliers, often in the hundreds of kilograms for bulk oil, impacting smaller brands. Margin expectations vary wildly; while commodity fish oils offer thin margins, novel algal sources or highly purified, condition-specific formulations can command premiums. Lead times for specialised ingredients, particularly high-purity algal DHA, can extend to 12-16 weeks, necessitating robust supply chain planning.

What This Means for Norway

Norway, with its rich fishing heritage and stringent environmental regulations, holds a unique position in the omega-3 market. While its traditional fish oil industry faces increasing pressure regarding sustainability and traceability, there's a burgeoning interest in leveraging aquaculture by-products for omega-3 extraction, aligning with circular economy principles. Norwegian consumers, generally highly health-conscious, are also demonstrating a growing preference for sustainably sourced and transparently labelled products. This creates both a challenge and an opportunity: to innovate within the traditional sector while also exploring novel, local aquaculture-derived or even algal-based omega-3 sources to meet evolving demands and maintain a competitive edge against global suppliers.

The Bottom Line for Formulators

Formulators should invest in omega-3s, but with discernment. Prioritise stability, bioavailability (triglyceride forms, for instance), and verifiable sustainability over raw concentration figures. Consider algal oils for their sustainable profile and high DHA content, despite often higher initial cost and longer lead times. For fish oils, demand robust third-party certifications for purity and sustainability (e.g., Friend of the Sea, GOED). The market rewards quality, transparency, and genuine innovation, not merely the highest number on a label.